Goldman Sachs’s CASI Pharmaceuticals CASI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-24,468
| Closed | -$20K | – | 5704 |
|
|
2022
Q1 | $20K | Sell |
24,468
-25,928
| -51% | -$21.2K | ﹤0.01% | 5610 |
|
|
2021
Q4 | $40K | Sell |
50,396
-149,590
| -75% | -$119K | ﹤0.01% | 5384 |
|
|
2021
Q3 | $238K | Buy |
199,986
+48,803
| +32% | +$58.1K | ﹤0.01% | 4784 |
|
|
2021
Q2 | $234K | Buy |
151,183
+89,131
| +144% | +$138K | ﹤0.01% | 4842 |
|
|
2021
Q1 | $149K | Buy |
62,052
+32,473
| +110% | +$78K | ﹤0.01% | 4937 |
|
|
2020
Q4 | $87K | Sell |
29,579
-147,052
| -83% | -$433K | ﹤0.01% | 4490 |
|
|
2020
Q3 | $271K | Buy |
176,631
+165,010
| +1,420% | +$253K | ﹤0.01% | 3945 |
|
|
2020
Q2 | $29K | Sell |
11,621
-17,492
| -60% | -$43.7K | ﹤0.01% | 4290 |
|
|
2020
Q1 | $59K | Sell |
29,113
-18,786
| -39% | -$38.1K | ﹤0.01% | 4248 |
|
|
2019
Q4 | $148K | Buy |
47,899
+13,001
| +37% | +$40.2K | ﹤0.01% | 4067 |
|
|
2019
Q3 | $117K | Buy |
34,898
+16,708
| +92% | +$56K | ﹤0.01% | 4026 |
|
|
2019
Q2 | $58K | Sell |
18,190
-15,241
| -46% | -$48.6K | ﹤0.01% | 4075 |
|
|
2019
Q1 | $96K | Buy |
33,431
+4,283
| +15% | +$12.3K | ﹤0.01% | 4018 |
|
|
2018
Q4 | $118K | Buy |
29,148
+631
| +2% | +$2.55K | ﹤0.01% | 3865 |
|
|
2018
Q3 | $133K | Buy |
+28,517
| New | +$133K | ﹤0.01% | 3895 |
|
|
2018
Q2 | – | Sell |
-178,063
| Closed | -$743K | – | 4175 |
|
|
2018
Q1 | $743K | Buy |
178,063
+159,202
| +844% | +$664K | ﹤0.01% | 3316 |
|
|
2017
Q4 | $61K | Buy |
+18,861
| New | +$61K | ﹤0.01% | 4022 |
|
|
2016
Q4 | – | Sell |
-24,751
| Closed | -$27K | – | 4453 |
|
|
2016
Q3 | $27K | Sell |
24,751
-5,428
| -18% | -$5.92K | ﹤0.01% | 4404 |
|
|
2016
Q2 | $35K | Buy |
+30,179
| New | +$35K | ﹤0.01% | 4325 |
|